Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1442740
This article is part of the Research Topic Obesity and Metabolism in Endocrine-Related Cancers View all articles

Association Between Metabolic Obesity Phenotypes and the Risk of Developing Prostate Cancer: A Propensity Score Matching Study Based on Xinjiang

Provisionally accepted
Jinru Wang Jinru Wang 1Aireti Apizi Aireti Apizi 2Hao Qiu Hao Qiu 1Ning Tao Ning Tao 1*Hengqing An Hengqing An 2*
  • 1 School of Public Health, Xinjiang Medical University, Urumqi, China
  • 2 First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur Region, China

The final, formatted version of the article will be published soon.

    Background: Obesity-induced metabolic dysfunction increases the risk of developing tumors, however, the relationship between metabolic obesity phenotypes and prostate cancer (PCa) remains unclear.The term metabolic obesity phenotypes was introduced based on metabolic status and BMI categories. Participants were categorized into four groups: metabolically healthy nonobesity (MHNO), metabolically healthy obesity (MHO), metabolically unhealthy nonobesity (MUNO), and metabolically unhealthy obesity (MUO). Propensity score matching was conducted based on age, ethnicity, marriage, etc. Univariate and multivariate conditional logistic regression analyses were used to assess the relationship between metabolic obesity phenotypes, metabolic risk factors, and PCa. Sensitivity analysis was performed to verify the robustness of the results.Results: After propensity score matching among 564 PCa patients and 1418 healthy individuals, 209 were selected for each of the case and control groups. There were no statistically significant differences in the basic characteristics between the two groups. Univariate and multivariate conditional logistic regression suggested that the risk of developing PCa in both MHO and MUO individuals was higher than in MHNO individuals. Specifically, the risk of developing PCa in MHO individuals was 2.166 times higher than in MHNO individuals (OR=2.166, 95%CI: 1.133-4.139), and the risk in MUO individuals was is 2.398 times higher than in MHNO individuals(OR=2.398, 95%CI:1.271-4.523). Individuals with hyperglycemia and elevated triglycerides also had a higher risk of developing PCa (hyperglycemia :OR=1.488, 95%CI: 1.001-2.210; elevated triglycerides: OR=2.292, 95%CI: 1.419-3.702). Those with more than or equal to three metabolic risk factors had an increased risk of PCa (OR=1.990, 95%CI: 1.166-3.396). Sensitivity analysis indicated an increased risk of PCa in MUO individuals compared to MHNO individuals.In this retrospective study, individuals with MHO and MUO had a higher risk of developing PCa.

    Keywords: Prostate cancer1, metabolic obesity phenotypes2, Propensity score matching3, metabolic risk factors4, conditional logistic regression5

    Received: 02 Jun 2024; Accepted: 19 Jul 2024.

    Copyright: © 2024 Wang, Apizi, Qiu, Tao and An. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ning Tao, School of Public Health, Xinjiang Medical University, Urumqi, China
    Hengqing An, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur Region, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.